Capital World Investors (ORKA) reports 5.6% beneficial stake in Oruka Therapeutics

Rhea-AI Filing Summary

Capital World Investors, a division of Capital Research and Management Company and its investment management affiliates, reports beneficial ownership of Oruka Therapeutics, Inc. common stock. The group is deemed to beneficially own 3,401,639 shares, representing 5.6% of Oruka’s 60,312,101 shares believed to be outstanding.

Capital World Investors holds sole voting power and sole dispositive power over all 3,401,639 shares, with no shared voting or dispositive power reported. The filing is signed by Timothy J. Moon, Vice President and Senior Counsel of Capital Research and Management Company.

Key Figures

Shares beneficially owned: 3,401,639 shares Percent of class: 5.6% Shares believed outstanding: 60,312,101 shares +4 more

7 metrics

Shares beneficially owned 3,401,639 shares Common stock beneficially owned by Capital World Investors

Percent of class 5.6% Percentage of Oruka Therapeutics common stock class owned

Shares believed outstanding 60,312,101 shares Total Oruka Therapeutics common shares believed to be outstanding

Sole voting power 3,401,639 shares Shares over which Capital World Investors has sole voting power

Shared voting power 0 shares Shares over which Capital World Investors has shared voting power

Sole dispositive power 3,401,639 shares Shares over which Capital World Investors has sole dispositive power

Shared dispositive power 0 shares Shares over which Capital World Investors has shared dispositive power

Key Terms

Schedule 13G, beneficial owner, sole voting power, dispositive power, +1 more

5 terms

Schedule 13G regulatory

"Capital World Investors files a Schedule 13G reporting its beneficial ownership"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficial owner financial

"CWI is deemed to be the beneficial owner of 3,401,639 shares or 5.6%"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

sole voting power financial

"Sole power to vote or to direct the vote: 3,401,639"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole power to dispose or to direct the disposition of: 3,401,639"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

percent of class financial

"Percent of class: 5.6 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 05:42 PM Accepted by SEC EDGAR 08/12/2026 - 05:40 PM Learn about SEC filing dates

FAQ

What percentage of Oruka Therapeutics (ORKA) does Capital World Investors report owning?

Capital World Investors reports beneficial ownership of 5.6% of Oruka Therapeutics’ common stock, representing 3,401,639 shares out of 60,312,101 shares believed to be outstanding, according to the Schedule 13G filing.

How many Oruka Therapeutics (ORKA) shares does Capital World Investors control the vote for?

Capital World Investors reports sole voting power over 3,401,639 Oruka Therapeutics shares. The filing states there is no shared voting power with any other party for these shares.

Does Capital World Investors share dispositive power over Oruka Therapeutics (ORKA) stock?

No. The filing reports sole dispositive power over 3,401,639 Oruka Therapeutics shares and 0 shares subject to shared dispositive power, indicating Capital World Investors alone directs disposition of these reported shares.

How many Oruka Therapeutics (ORKA) shares are believed to be outstanding in this Schedule 13G?

The Schedule 13G states that 60,312,101 Oruka Therapeutics common shares are believed to be outstanding. Capital World Investors’ 3,401,639 beneficially owned shares represent 5.6% of this total base.

Who signed the Schedule 13G related to Oruka Therapeutics (ORKA) for Capital World Investors?

The Schedule 13G is signed by Timothy J. Moon, identified as Vice President and Senior Counsel of Capital Research and Management Company, on behalf of Capital World Investors.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Oruka Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

687604108

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 687604108

1

Names of Reporting Persons

Capital World Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,401,639.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,401,639.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,401,639.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Oruka Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 855 Oak Grove Avenue, Suite 100, Menlo Park, CA 94025
Item 2.
(a)	Name of person filing: Capital World Investors
(b)	Address or principal business office or, if none, residence: 333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 687604108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,401,639 ** **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 3,401,639 shares or 5.6% of the 60,312,101 shares believed to be outstanding.
(b)	Percent of class: 5.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,401,639
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,401,639
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital World Investors

Signature:	Timothy J. Moon
Name/Title:	Vice President and Senior Counsel, Capital Research and Management Company
Date:	08/11/2026